Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Oral combination of HMAs + venetoclax in unfit or elderly patients with AML

Farhad Ravandi • 11 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Azacitidine Decitabine Venetoclax

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination of hypomethylating agents (HMA) with venetoclax in elderly and unfit patients with acute myeloid leukemia (AML), commenting on the benefits of an all-oral treatment regimen in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals